Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Topics Diabetes Fierce 50 Special Report Awards Gala Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Subscribe Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Topics Diabetes Fierce 50 Special Report Awards Gala Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech MediGene sells European rights to Oracea By John Carroll Jul 31, 2008 10:15am MediGene has sold the European rights to Oracea for rosacea to Galderma Laboratories for €8 million upfront and up to €32 million in total based on certain commercialization milestones. Release